Inhibitors of PD1 (such as nivolumab and pembrolizumab) and PD-L1 (such as atezolizumab) opened new possibilities for patients with advanced lung cancer, by reactivating the body’s own immune system which recognizes and destroys cancer cells31. This evidence concerns the gene CD274 and lung carcinoma.